The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Methotrexate oral solution (Brand name: Xatmep)
- Manufactured by
Silvergate Pharmaeuticals, Inc.
FDA-approved indication: April 2017, methotrexate oral solution (Xatmep) was approved for the treatment of oligoarticular juvenile idiopathic arthritis (persistent oligoarthritis, psoriatic juvenile idiopathic arthritis, enthesitis-related arthritis, or undifferentiated arthritis) and polyarticular juvenile idiopathic arthritis in children 0 through 16 years of age.
National Library of Medicine Drug Information Portal